康缘药业(600557.SH)：计划2026年三季度进入III期临床

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) is advancing its innovative drug ZX2010 injection for the treatment of type 2 diabetes and obesity, with key clinical milestones set for 2025 and 2026 [1] Group 1 - The first subject enrollment for the Phase II clinical trial of ZX2010 is expected to be completed by July 2025 [1] - The company has initiated enrollment in three out of four planned dosage groups for the Phase II trial [1] - The company plans to enter Phase III clinical trials in the third quarter of 2026 [1]